BRPI0916282B8 - uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica - Google Patents
uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônicaInfo
- Publication number
- BRPI0916282B8 BRPI0916282B8 BRPI0916282A BRPI0916282A BRPI0916282B8 BR PI0916282 B8 BRPI0916282 B8 BR PI0916282B8 BR PI0916282 A BRPI0916282 A BR PI0916282A BR PI0916282 A BRPI0916282 A BR PI0916282A BR PI0916282 B8 BRPI0916282 B8 BR PI0916282B8
- Authority
- BR
- Brazil
- Prior art keywords
- renal failure
- chronic renal
- pgi2
- treatment
- receptor agonist
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 3
- 102000009079 Epoprostenol Receptors Human genes 0.000 title 1
- 108010073099 Epoprostenol Receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
uso de composto na preparação de um agente para tratamento de insuficiência renal crônica. a presente invenção refere-se a um agente terapêutico para insuficiência renal crônica que compreende como um ingrediente eficaz um composto representado pela fórmula geral (1) ou um sal farmaceuticamente aceitável do mesmo. ou seja, a presente invenção proporciona a provisão de um fármaco que compreende como um ingrediente eficaz um composto representado pela fórmula geral (1) ou um sal farmaceuticamente aceitável do mesmo, tal fármaco é útil não só para a melhora de função renal, como também para a melhora de anemia, ativação de sod e excreção de substância urêmicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008190085 | 2008-07-23 | ||
| PCT/JP2009/063153 WO2010010909A1 (ja) | 2008-07-23 | 2009-07-23 | 慢性腎不全処置剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0916282B1 BRPI0916282B1 (pt) | 2019-10-29 |
| BRPI0916282B8 true BRPI0916282B8 (pt) | 2021-05-25 |
Family
ID=41570369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0916282A BRPI0916282B8 (pt) | 2008-07-23 | 2009-07-23 | uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8575175B2 (pt) |
| EP (1) | EP2305653B9 (pt) |
| JP (1) | JP5609643B2 (pt) |
| KR (1) | KR101587071B1 (pt) |
| CN (1) | CN102105453B (pt) |
| BR (1) | BRPI0916282B8 (pt) |
| CA (1) | CA2730599C (pt) |
| ES (1) | ES2532858T3 (pt) |
| MX (1) | MX2011000897A (pt) |
| MY (1) | MY163762A (pt) |
| PL (1) | PL2305653T3 (pt) |
| WO (1) | WO2010010909A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX346318B (es) | 2009-06-26 | 2017-03-15 | Nippon Shinyaku Co Ltd | Cristales. |
| WO2011024874A1 (ja) * | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
| ES2693622T3 (es) | 2011-01-13 | 2018-12-13 | SciPharm S.à r.l. | Método para mejorar el injerto de células madre hematopoyéticas |
| WO2015129750A1 (ja) * | 2014-02-26 | 2015-09-03 | 日本臓器製薬株式会社 | 慢性腎臓病の進行抑制又は改善剤 |
| WO2018019296A1 (zh) * | 2016-07-29 | 2018-02-01 | 成都苑东生物制药股份有限公司 | 氨基吡嗪类化合物或盐、异构体、其制备方法及用途 |
| CA3130536A1 (en) | 2016-10-06 | 2018-04-12 | Daiichi Sankyo Company, Limited | Urea derivative |
| EP4371617A3 (en) | 2017-09-28 | 2024-08-07 | Nippon Shinyaku Co., Ltd. | Crystal |
| TW201922230A (zh) | 2017-11-16 | 2019-06-16 | 日商日本新藥股份有限公司 | 控釋製劑 |
| KR102041916B1 (ko) | 2017-12-15 | 2019-11-08 | (주)녹십자웰빙 | 신장질환 진행 억제 및 예방용 프로바이오틱스 및 이를 포함하는 신장질환 진행 억제 및 예방용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH093973A (ja) | 1995-06-26 | 1997-01-07 | Kubota Corp | 作業機械の走行装置 |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| JP3181859B2 (ja) | 1997-07-08 | 2001-07-03 | 三菱電機株式会社 | 電力変換装置 |
| JPH1121843A (ja) | 1997-07-08 | 1999-01-26 | Nippon Kaiyo Consultant Kk | 海水循環方法 |
| AUPP003297A0 (en) | 1997-10-27 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | 4,5-diaryloxazole compounds |
| AUPP109097A0 (en) | 1997-12-22 | 1998-01-22 | Fujisawa Pharmaceutical Co., Ltd. | Napthalene derivatives |
| JP2000067748A (ja) | 1998-08-26 | 2000-03-03 | Matsushita Electronics Industry Corp | カラー陰極線管の製造方法 |
| US6335459B1 (en) | 1998-12-23 | 2002-01-01 | Syntex (U.S.A.) Llc | Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators |
| US20030036513A1 (en) | 1999-02-16 | 2003-02-20 | Yurkow Edward J. | Method for treating cancer |
| CA2337213C (en) * | 1999-05-10 | 2010-05-04 | Toray Industries, Inc. | Therapeutic agent for renal failure containing 4,8-inter-m-phenylene prostaglandin i2 derivative |
| JP3858521B2 (ja) | 1999-06-28 | 2006-12-13 | 松下電器産業株式会社 | 移動体識別装置 |
| AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| ATE260281T1 (de) | 2000-08-03 | 2004-03-15 | Pfizer Prod Inc | Diazacyclooctanverbindungen und ihre therapeutische verwendung |
| TWI316055B (pt) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| US7104566B2 (en) | 2002-04-25 | 2006-09-12 | Delphi Technologies, Inc. | Airbag module and cover arrangement |
| JP4340111B2 (ja) | 2003-08-08 | 2009-10-07 | 大成化工株式会社 | ポンプ容器 |
| JP4906514B2 (ja) | 2003-12-16 | 2012-03-28 | ユナイテッド セラピューティクス コーポレイション | 腎臓機能改善のためのトレプロスチニルの用途 |
| PL364348A1 (en) | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| JP4694900B2 (ja) | 2005-06-28 | 2011-06-08 | 株式会社ディスコ | レーザー加工方法 |
| JP5018478B2 (ja) | 2005-07-08 | 2012-09-05 | 東レ株式会社 | 尿毒症改善のための治療剤および処置方法 |
| ES2817557T3 (es) | 2008-02-28 | 2021-04-07 | Nippon Shinyaku Co Ltd | Inhibidor de fibrosis |
| JP5851246B2 (ja) * | 2008-12-30 | 2016-02-03 | リグスホスピタルＲｉｇｓｈｏｓｐｉｔａｌｅｔ | 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物 |
| MX346318B (es) | 2009-06-26 | 2017-03-15 | Nippon Shinyaku Co Ltd | Cristales. |
-
2009
- 2009-07-23 CA CA2730599A patent/CA2730599C/en active Active
- 2009-07-23 CN CN200980128581.4A patent/CN102105453B/zh active Active
- 2009-07-23 US US13/055,242 patent/US8575175B2/en active Active
- 2009-07-23 KR KR1020117000559A patent/KR101587071B1/ko active Active
- 2009-07-23 WO PCT/JP2009/063153 patent/WO2010010909A1/ja not_active Ceased
- 2009-07-23 BR BRPI0916282A patent/BRPI0916282B8/pt not_active IP Right Cessation
- 2009-07-23 MX MX2011000897A patent/MX2011000897A/es unknown
- 2009-07-23 PL PL09800423T patent/PL2305653T3/pl unknown
- 2009-07-23 MY MYPI2011000305A patent/MY163762A/en unknown
- 2009-07-23 EP EP09800423.7A patent/EP2305653B9/en active Active
- 2009-07-23 JP JP2010521726A patent/JP5609643B2/ja active Active
- 2009-07-23 ES ES09800423.7T patent/ES2532858T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5609643B2 (ja) | 2014-10-22 |
| CA2730599A1 (en) | 2010-01-28 |
| WO2010010909A1 (ja) | 2010-01-28 |
| CN102105453A (zh) | 2011-06-22 |
| HK1159104A1 (zh) | 2012-07-27 |
| EP2305653A1 (en) | 2011-04-06 |
| MX2011000897A (es) | 2011-03-30 |
| EP2305653B9 (en) | 2015-06-24 |
| MY163762A (en) | 2017-10-31 |
| US8575175B2 (en) | 2013-11-05 |
| EP2305653A4 (en) | 2012-05-16 |
| JPWO2010010909A1 (ja) | 2012-01-05 |
| EP2305653B1 (en) | 2015-03-04 |
| PL2305653T3 (pl) | 2015-08-31 |
| US20110178103A1 (en) | 2011-07-21 |
| CN102105453B (zh) | 2016-05-25 |
| KR101587071B1 (ko) | 2016-01-20 |
| BRPI0916282B1 (pt) | 2019-10-29 |
| ES2532858T3 (es) | 2015-04-01 |
| ES2532858T9 (es) | 2015-07-03 |
| CA2730599C (en) | 2016-09-13 |
| KR20110036572A (ko) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BRPI0706992C8 (pt) | composto de fórmula (i) e formulação farmacêutica | |
| BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
| BRPI0914902B8 (pt) | Composição farmacêutica para uso no tratamento de mal de parkinson | |
| BR112015008480A2 (pt) | compostos de benzeno substituído | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| BR112012009376B8 (pt) | composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica | |
| CL2007001427A1 (es) | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| BRPI0618239A8 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos | |
| BR112014018953A8 (pt) | Derivados de lupano triterpenoide e uso farmacêutico dos mesmos | |
| BRPI0508540A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
| BRPI0913291A2 (pt) | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto | |
| BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
| BRPI0921097B8 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
| MY163762A (en) | Therapeutic agent for chronic renal failure | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX2009010374A (es) | Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2680 DE 17-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |